Search in:

Advanced search

Clinical Ophthalmology Volume 11, 2017 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Original Research

Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial

Ron P Gallemore1 Retina Macula Institute, Torrance, CACorrespondence[email protected]

Josh Wallsh1 Retina Macula Institute, Torrance, CA

Henry L Hudson2 Retina Centers PC, Tucson, AZ

Allen C Ho3 Wills Eye Institute, Philadelphia, PA

Richard Chace4 Eyesight Ophthalmic Services, Portsmouth, NH

Joel Pearlman5 Retinal Consultants Medical Group, Sacramento, CA, USA

Pages 223-231 | Published online: 24 Jan 2017

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

BrownDMKaiserPKMichelsMfor the ANCHOR Study GroupRanibizumab versus verteporfin for neovascular age-related macular degenerationN Engl J Med2006355141432144417021319
PubMed Web of Science ®Google Scholar
RosenfeldPJBrownDMHeierJSfor the MARINA Study GroupRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
PubMed Web of Science ®Google Scholar
Schmidt-ErfurthUClinical safety of ranibizumab in age-related macular degenerationExpert Opin Drug Saf20109114916520001757
PubMed Web of Science ®Google Scholar
KleinKSWalshMKHassanTSEndophthalmitis after anti-VEGF injectionsOphthalmology20091166122519486799
PubMed Web of Science ®Google Scholar
DhallaMSShahGKBlinderKJRyanEHJrMittraRATewariACombined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degenerationRetina200626998899317151484
PubMed Web of Science ®Google Scholar
LazicRGabricNVerteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degenerationOphthalmology200711461179118517544776
PubMed Web of Science ®Google Scholar
PotterMJClaudioCCSzaboSMA randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA studyBr J Ophthalmol201094217417919520690
PubMed Web of Science ®Google Scholar
KaiserPKBoyerDSGarciaRRegistry of Visudyne AMD Therapy Writing Committee. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degenerationOphthalmology2009116474775519243834
PubMed Web of Science ®Google Scholar
AugustinAJPulsSOffermannITriple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasoneRetina200727213314017290193
PubMed Web of Science ®Google Scholar
AntoszykANTuomiLChungCYSinghAFOCUS Study GroupRanibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 resultsAm J Ophthalmol2008145586287418321465
PubMed Web of Science ®Google Scholar
Schmidt-ErfurthUWolfSPROTECT Study GroupSame-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degenerationBr J Ophthalmol200892121620162719029163
PubMed Web of Science ®Google Scholar
SmithBTDhallaMSShahGKBlinderKJRyanEHJrMittraRAIntravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degenerationRetina200828567568118463509
PubMed Web of Science ®Google Scholar
WilliamsPDCallananDSolleyWAveryRLPieramiciDJAabergTA prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degenerationClin Ophthalmol201261519152523055673
PubMedGoogle Scholar
HatzKSchneiderUHenrichPBBraunBSacuSPrünteCRanibizumab plus verteporfin photodynamic therapy in neovascular age-related macular degeneration: 12 months of retreatment and vision outcomes from a randomized studyOphthalmologica20152332667325471330
PubMed Web of Science ®Google Scholar
YipPPWooCFTangHHHoCKTriple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinoloneBr J Ophthalmol200993675475819273471
PubMed Web of Science ®Google Scholar
GallemoreRPNguyenDWhen anti-VEGF treatment failsRev Opthalmol20081503
Google Scholar
ShahGKSangDNHughesMSVerteporfin combination regimens in the treatment of neovascular age-related macular degenerationRetina200929213314819202423
PubMed Web of Science ®Google Scholar
VISUDYNE^® Verteporfin for Injection) Full Prescribing InformationBridgewater, NJ, USAValeant Ophthalmics2013 Available from: http://www.bausch.com/Portals/77/-/m/BL/United%20States/Files/Package%20Inserts/Pharma/visudyne-package-insert.pdfAccessed June 2, 2016
Google Scholar
RegilloCDBrownDMAbrahamPfor the PIER Study GroupRandomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1Am J Ophthalmol2008145223924818222192
PubMed Web of Science ®Google Scholar
FungAELalwaniGARosenfeldPJAn optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related degeneration (AMD)Am J Ophthalmol2007143456658317386270
PubMed Web of Science ®Google Scholar
LalwaniGARosenfeldPJFungAEA variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO studyAm J Ophthalmol2009148143.e158.e119376495
PubMed Web of Science ®Google Scholar
BusbeeBGHoACBrownDMHARBOR Study GroupTwelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degenerationOphthalmology201312051046105623352196
PubMed Web of Science ®Google Scholar
MartinDFMaguireMGYingGSGrunwaldJEFineSLJaffeGJCATT Research GroupRanibizumab and bevacizumab for neovascular age-related macular degenerationN Engl J Med2011364201897190821526923
PubMed Web of Science ®Google Scholar
MartinDFMaguireMGFineSLComparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupRanibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two year resultsOphthalmology201211971388139822555112
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date